StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Research & Development Expense by Quarter

Research & Development Expense — Pharmaceutical Segment ($M) ($M)

QuarterlyAnnual

Merck Research & Development Expense: $0M in Q2 2026. That is the highest of the 10 quarters on record here.

Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-07) ↗

Reported in Form 10-Q / 10-K Segment Footnote & MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedResearch & Development Expense — Pharmaceutical Segment ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20260–Form 10-Q (filed 2026-08-07) ↗
Q1 2026Mar 31, 20260–Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 20250–Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 20250–Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 20250–Form 10-Q (filed 2026-08-07) ↗
Q1 2025Mar 31, 20250–Form 10-Q (filed 2026-05-04) ↗
Q4 2024Dec 31, 20240–Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 20240–Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 20240–Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 20240–Form 10-Q (filed 2025-05-02) ↗

Breakdown

What makes up research & Development Expense

Cite this data

StockData. (2026). Merck Research & Development Expense ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rd-seg-pharma

See every metric in the Merck KPI table. Data updated Oct 26, 2026.